.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Healthtrust
Daiichi Sankyo
Merck
McKinsey
Cipla
Cerilliant
Johnson and Johnson
Julphar

Generated: November 25, 2017

DrugPatentWatch Database Preview

NIRAVAM Drug Profile

« Back to Dashboard

What is the patent landscape for Niravam, and what generic Niravam alternatives are available?

Niravam is a drug marketed by Ucb Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixteen patent family members in nine countries.

The generic ingredient in NIRAVAM is alprazolam. There are fifteen drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the alprazolam profile page.

Pharmacology for NIRAVAM

Ingredient-typeBenzodiazepines
Drug ClassBenzodiazepine

Medical Subject Heading (MeSH) Categories for NIRAVAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-001Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-004Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-002Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-004Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-001Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-002Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-003Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
NIRAVAM
alprazolam
TABLET, ORALLY DISINTEGRATING;ORAL021726-003Jan 19, 2005DISCNYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NIRAVAM

Drugname Dosage Strength RLD Submissiondate
alprazolamOrally Disintegrating Tablets0.25 mg, 0.5 mg, 1 mg and 2 mgNiravam12/27/2005

International Patent Family for Tradename: NIRAVAM

Country Document Number Estimated Expiration
European Patent Office0975336► Subscribe
Denmark2147669► Subscribe
Canada2284663► Subscribe
Japan2001524956► Subscribe
Portugal2147669► Subscribe
Spain2525720► Subscribe
Australia726336► Subscribe
Japan2008001726► Subscribe
European Patent Office2147669► Subscribe
World Intellectual Property Organization (WIPO)9846215► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Mallinckrodt
McKesson
Deloitte
Colorcon
Fuji
Federal Trade Commission
UBS
Moodys
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot